BFM
RGLS

Boothbay Fund Management’s Regulus Therapeutics RGLS Stock Holding History

Boothbay Fund Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-11,583
Closed -$24K – 2547
2022
Q2 		$24K Sell
11,583
-823
-7% -$2K ﹤0.01% 2179
2022
Q1 		$37K Hold
12,406
– – ﹤0.01% 2204
2021
Q4 		$39K Hold
12,406
– – ﹤0.01% 1786
2021
Q3 		$86K Sell
12,406
-1,757
-12% -$12.9K ﹤0.01% 1814
2021
Q2 		$115K Hold
14,163
– – ﹤0.01% 1721
2021
Q1 		$221K Buy
+14,163
New +$210K 0.01% 1322

Other funds holding RGLS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boothbay Fund Management's RGLS Position: Q3 2022 in Review

Boothbay Fund Management sold out of Regulus Therapeutics (RGLS) in Q3 2022, closing a stake of 11,583 shares — an estimated $24K sold.

Boothbay Fund Management first reported a position in RGLS in Q1 2021 and held it in 6 quarters. The position peaked at $221K in Q1 2021. 24 funds tracked by Wall St. Rank hold RGLS as of Q3 2022.

  • Boothbay Fund Management reported no remaining Regulus Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Boothbay Fund Management sold 11,583 Regulus Therapeutics shares in Q3 2022, an estimated $24K.
  • Boothbay Fund Management first reported a position in Regulus Therapeutics in Q1 2021 and held it in 6 quarters.
  • Boothbay Fund Management's Regulus Therapeutics position peaked at $221K in Q1 2021.
  • 24 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2022.

Based on Boothbay Fund Management's 13F filing for Q3 2022, filed 14 Nov 2022.